Comparison of Serum Uric Acid Levels in Ischemic Heart Disease Patients Taking Atorvastatin with those on Rosuvastatin

Aakash Aslam; Tariq Bashir tareen; Farhan Zaid; Ahsan Tanveer; Jamshaid Iqbal; Hafiz Muhammad  Umer

doi:10.51253/pafmj.v76i1.11725

Authors

Aakash Aslam Department of Medicine, Combined Military Hospital, Sialkot/National University of Medical Sciences (NUMS) Pakistan
Tariq Bashir tareen Department of Medicine, Combined Military Hospital, Sialkot/National University of Medical Sciences (NUMS) Pakistan
Farhan Zaid Department of Medicine, Combined Military Hospital, Malir/National University of Medical Sciences (NUMS) Pakistan
Ahsan Tanveer Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/ National University of Medical Sciences (NUMS) Pakistan
Jamshaid Iqbal Department of Medicine, Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS) Pakistan
Hafiz Muhammad Umer Department of Medicine, Combined Military Hospital, Quetta/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i1.11725

Keywords:

Atorvastatin, Ischemic heart disease, Rosuvastatin, Uric acid

Abstract

Objective: To compare serum uric acid levels in stable ischemic heart disease patients taking Atorvastatin versus those taking Rosuvastatin.

Study Design: Quasi-experimental study.

Place and Duration of Study: Combined Military Hospital, Sialkot Pakistan, from Dec 2022 to Dec 2023.

Methodology: A total of 42 patients with stable ischemic heart disease were included in the study. 21 patients were placed in “Atorvastatin Group” and 21 were placed in “Rosuvastatin Group”. Baseline serum uric acid levels were documented. Patients received respective statin therapy and after three months, serum uric acid levels were rechecked in both Groups.

Results: Mean age was 45.73±5.01 years. There were 29(69.05%) males and 13(30.95%) females. Mean body mass index was 30.92±3.35 kg/m². Mean duration of stable ischemic heart disease was 8.19±1.48 months. 33(78.57%) were smokers. 34(80.95%) were diabetics. 35 (83.33%) had hypertension. In Atorvastatin Group (n = 21), mean post-therapy serum uric acid was 5.11±0.42 mg/dl while in Rosuvastatin Group (n=21) it was 5.60±0.44 mg/dl, (p=0.001).

Conclusion: Serum uric acid level was significantly lower with the use of Atorvastatin as compared to Rosuvastatin therapy

Downloads

Download data is not yet available.

References

1. Fu X, Wang J, Jiang S, Wu J, Mu Z, Tang Y, et al. Mortality trend analysis of ischemic heart disease in China between 2010 and 2019: a joinpoint analysis. BMC Public Health 2023; 23(1): 644.

https://doi.org/10.1186/s12889-023-15549-3

2. Safiri S, Karamzad N, Singh K, Carson-Chahhoud K, Adams C, Nejadghaderi SA, et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019. Eur J Prev Cardiol 2022; 29(2): 420-431.

https://doi.org/10.1093/eurjpc/zwab213

3. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus 2020; 12(7): e9349. https://doi.org/10.7759/cureus.9349

4. Padda J, Khalid K, Almanie AH, Al Hennawi H, Mehta KA, Wijeratne Fernando R, et al. Hyperuricemia in patients with coronary artery disease and its association with disease severity. Cureus 2021; 13(8): e17161.

https://doi.org/10.7759/cureus.17161

5. Creber RM, Dimagli A, Spadaccio C, Myers A, Moscarelli M, Demetres M, et al. Effect of coronary artery bypass grafting on quality of life: a meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes 2022; 8(3): 259-268.

https://doi.org/10.1093/ehjqcco/qcab075

6. Santucci A, Riccini C, Cavallini C. Treatment of stable ischaemic heart disease: the old and the new. Eur Heart J Suppl 2020; 22(Suppl E): E54-E59.

https://doi.org/10.1093/eurheartj/suaa060

7. Van Rosendael AR, Van den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, et al. Association of statin treatment with progression of coronary atherosclerotic plaque composition. JAMA Cardiol 2021; 6(11): 1257-1266.

https://doi.org/10.1001/jamacardio.2021.3055

8. Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The effect of statin therapy on serum uric acid levels: a systematic review and meta-analysis. Curr Med Chem 2023; 31(13): 1726-1739. https://doi.org/10.2174/0929867330666230207124516

9. Lardizabal JA, Deedwania PC. The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep 2011; 13(1): 43-50. https://doi.org/10.1007/s11883-010-0147-y

10. Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H. Effects on serum uric acid by difference of the renal protective effects with Atorvastatin and Rosuvastatin in chronic kidney disease patients. Biol Pharm Bull 2014; 37(2): 226-231.

https://doi.org/10.1248/bpb.b13-00418

11. Jang AY, Lim S, Jo SH, Han SH, Koh KK. New trends in dyslipidemia treatment. Circ J 2021; 85(6): 759-768.

https://doi.org/10.1253/circj.CJ-20-1037

12. Kim K, Ginsberg HN, Choi SH. New, Novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J 2022; 46(4): 517-532.

https://doi.org/10.4093/dmj.2022.0198

13. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krähenbühl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res 2020; 154: 104201.

https://doi.org/10.1016/j.phrs.2019.03.010

14. Sainz de Medrano Sainz JI, Brunet Serra M. Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions. Adv Lab Med 2023; 4(4): 341-352. https://doi.org/10.1515/almed-2023-0123

15. Leung N, Yip K, Pillinger MH, Toprover M. Lowering and raising serum urate levels: off-label effects of commonly used medications. Mayo Clin Proc 2022; 97(7): 1345-1362.

https://doi.org/10.1016/j.mayocp.2022.02.027

16. Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. Front Pharmacol 2023; 14: 1096999.

https://doi.org/10.3389/fphar.2023.1096999

17. Suman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- does it really matters? Curr Probl Cardiol 2023; 48(5): 101604.

https://doi.org/10.1016/j.cpcardiol.2023.101604

18. Bai MF, Wang X. Risk factors associated with coronary heart disease in women: a systematic review. Herz 2020; 45(Suppl 1): 52-57. https://doi.org/10.1007/s00059-019-4835-2

19. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation 2023; 147(8): e93-e621.

https://doi.org/10.1161/CIR.0000000000001123

20. Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of Atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci 2020; 36(6): 1334-1338. https://doi.org/10.12669/pjms.36.6.2945

21. Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (Atorvastatin, pitavastatin, and Rosuvastatin ) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids 2010; 29(4-6): 321-324.

https://doi.org/10.1080/15257771003741323

22. James R, Paul BJ. New and emerging therapies in gout. Rheumatol Autoimmun 2023; 3(2): 67-129.

https://doi.org/10.1002/rai2.12064

23. Palikhey A, Lodh A, Shrestha J, Karki M, Shrivastava AK. An effect of statin on serum uric acid in patients with dyslipidemia at a tertiary care hospital. Endocr Metab Sci 2023; 13: 100146.

https://doi.org/10.1016/j.endmts.2023.100146

24. Chen L, Qü P, Ding YC, Dong HJ, Liu ZZ, Huang LH et al. Effect of Rosuvastatin on serum uric acid levels in patients with hypercholesterolemia. J Dalian Med Uni 2012; 34(3): 266-269